吉非替尼与GP方案治疗晚期非小细胞肺癌的疗效比较

Efficacy Comparison of Gefitinib versus GP Regimen for Advanced Non-small Cell Lung Cancer

目的:探讨吉非替尼与GP方案(吉西他滨联合顺铂)治疗晚期非小细胞肺癌(NSCLC)患者的疗效及安全性。方法:对96例晚期NSCLC患者的资料进行回顾性分析。其中48例应用吉非替尼治疗的患者设为观察组,48例应用GP方案的患者设为对照组,观察两组患者的治疗效果及不良反应。结果:观察组患者的疾病控制率明显优于对照组患者(P<0.05),患者胸痛、血痰、上腔静脉压迫综合征(SVCS)等症状迅速改善(P<0.05),生活质量明显提高(P<0.05),且不良反应较为轻微。结论:吉非替尼对不能耐受或拒绝采用化疗的晚期NSCLC患者疗效较好,可提高患者的生活质量,且不良反应轻微,具有较好的临床应用前景。

OBJECTIVE：To evaluate the efficacy and safety of gefitinib versus GP regimen（gemcitabine plus cisplatin）for ad-vanced non-small cell lung cancer （NSCLC）. METHODS：The clinical data of 96 patients with advanced NSCLC were analyzed retrospectively. 48 cases in observation group were administered with gefitinib,and another 48 in control group were given GP regi-men. The therapeutic efficacy and adverse reactions were recorded. RESULTS：The disease control rate in the observation group was significantly better than in the control group （P〈0.05）,and the symptoms like chest pain,bloody sputum,compression superior vena cava syndrome（SVCS）relieved rapidly（P〈0.05）;the quality of life improved significantly（P〈0.05）and the adverse reac-tions were mild in these patients. CONCLUSIONS：Gefitinib treatment resulted in remarkable efficacy for those patients who can’t tolerate or reject using chemotherapy and it can improve the quality of life yet with mild adverse drug reactions which thus enjoys bright future in clinical application.